New 'Quad' antibody tested as last hope for tough blood cancers
NCT ID NCT05944978
Summary
This early-stage study is testing a new, experimental drug called GNC-035 in adults with chronic lymphocytic leukemia and other blood cancers that have come back or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shows any signs of helping to control the cancer. The drug is a special antibody designed to attack cancer cells in four different ways at once.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.